Search

Your search keyword '"Cavazzuti, M"' showing total 4 results
Start Over Author "Cavazzuti, M" Topic business.industry
4 results on '"Cavazzuti, M"'

1. Endovascular Treatment for Acute Ischemic Stroke

Author

Ciccone, A, Valvassori, L, Nichelatti, M, Sgoifo, A, Ponzio, M, Sterzi, R, Boccardi, E, SYNTHESIS Expansion Investigators: Gatti, A, Guccione, A, Motto, C, Santilli, I, Tortorella, R, Ferrante, E, Imbesi, F, Marazzi, R, Jann, S, Protti, A, Rizzone, M, Tiraboschi, P, Pero, G, Quilici, L, Piano, M, Zini, A, Casoni, F, Cavazzuti, M, Falzone, F, Nichelli, P, Vallone, S, Carpeggiani, P, Menetti, F, Guidotti, M, Checcarelli, N, Muscia, F, Martegani, A, Torgano, G, Mandelli, C, Zecca, B, Baron, P, Bersano, A, Branca, V, Isalberti, M, Papa, R, Paolucci, A, Magoni, M, Costa, A, Gamba, M, Gasparotti, R, Federico, F, Petruzzellis, M, Tartaglione, B, Mezzapesa, D, Chiumarulo, L, De Blasi, R, Agostoni, E, Botto, E, Longoni, M, Ballarini, V, Reganati, P, Malfatto, L, Rizzi, D, Serrati, C, Balestrino, M, Gandolfo, C, Castellan, L, Mavilio, N, Allegretti, L, Delodovici, Ml, Carimati, F, Verrengia, Ep, Bono, G, Perlasca, F, Craparo, G, Giorgianni, A, Azzini, C, De Vito, A, Tola, M, Saletti, A, Pozzessere, C, Corsi, F, Scifoni, G, Anticoli, S, Pezzella, Fr, Cotroneo, E, Gigli, R, Nencini, P, Palumbo, V, Pantoni, L, Inzitari, D, Mangiafico, S, Chinaglia, M, Russo, M, L'Erario, R, Amistà, P, Malferrari, G, Nucera, A, Zedde, Ml, Dallari, A, Deberti, G, Falaschi, F, Martignoni, A, Zappoli, F, Marcheselli, S, Stival, B, Presbitero, P, Rossi, Ml, Belli, G, Paciaroni, M, Caso, V, Agnelli, Gc, Hamam, M, Bovi, P, Piovan, Enrico, Sessa, M, Scomazzoni, F, Arnaboldi, M, Tancredi, L, Peroni, R, Censori, B, Poloni, M, Lunghi, S, Bonaldi, G, Donati, E, Magni, E, Pavia, M, Cobelli, M, Bottacchi, E, Corso, G, Tosi, P, Cordera, S, Di Giovanni, M, Giardini, G, Meloni, T, Cristoferi, M, Natrella, M, Ruiz, L, Dell'Acqua, Ml, Rolandi, G, Gallesio, I, Sandercock, P, Candelise, L, del Zoppo, G, Ciceri, E, Doneda, P, Daolio, M, Caputo, D, del Zotto, E, Cantisani, T., Ciccone, A, Valvassori, L, Nichelatti, M, Sgoifo, M, Ponzio, M, Sterzi, R, Boccardi, E, and Comi, Giancarlo

Subjects
Adult, Male, OCCLUSION, Psychoanalysis, RECANALIZATION, Neuroimaging, Article, law.invention, Brain Ischemia, TISSUE-PLASMINOGEN-ACTIVATOR, Randomized controlled trial, Fibrinolytic Agents, law, Case fatality rate, medicine, Humans, Single-Blind Method, PROUROKINASE, cardiovascular diseases, Adverse effect, Infusions, Intravenous, Stroke, Aged, Cerebral Hemorrhage, Thrombectomy, business.industry, Standard treatment, Endovascular Procedures, TISSUE-PLASMINOGEN-ACTIVATOR, CEREBRAL-ARTERY STROKE, RANDOMIZED-TRIAL, INTRAARTERIAL THROMBOLYSIS, INTRAVENOUS THROMBOLYSIS, OCCLUSION, REVASCULARIZATION, RECANALIZATION, PROUROKINASE, THROMBECTOMY, Atrial fibrillation, General Medicine, Odds ratio, Middle Aged, medicine.disease, INTRAARTERIAL THROMBOLYSIS, Combined Modality Therapy, RANDOMIZED-TRIAL, Cerebral Angiography, Treatment Outcome, Anesthesia, Tissue Plasminogen Activator, Acute Disease, REVASCULARIZATION, Female, INTRAVENOUS THROMBOLYSIS, CEREBRAL-ARTERY STROKE, business, Fibrinolytic agent
Abstract

In patients with ischemic stroke, endovascular treatment results in a higher rate of recanalization of the affected cerebral artery than systemic intravenous thrombolytic therapy. However, comparison of the clinical efficacy of the two approaches is needed.We randomly assigned 362 patients with acute ischemic stroke, within 4.5 hours after onset, to endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activator [t-PA], mechanical clot disruption or retrieval, or a combination of these approaches) or intravenous t-PA. Treatments were to be given as soon as possible after randomization. The primary outcome was survival free of disability (defined as a modified Rankin score of 0 or 1 on a scale of 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability despite symptoms, and 6 death) at 3 months.A total of 181 patients were assigned to receive endovascular therapy, and 181 intravenous t-PA. The median time from stroke onset to the start of treatment was 3.75 hours for endovascular therapy and 2.75 hours for intravenous t-PA (P0.001). At 3 months, 55 patients in the endovascular-therapy group (30.4%) and 63 in the intravenous t-PA group (34.8%) were alive without disability (odds ratio adjusted for age, sex, stroke severity, and atrial fibrillation status at baseline, 0.71; 95% confidence interval, 0.44 to 1.14; P=0.16). Fatal or nonfatal symptomatic intracranial hemorrhage within 7 days occurred in 6% of the patients in each group, and there were no significant differences between groups in the rates of other serious adverse events or the case fatality rate.The results of this trial in patients with acute ischemic stroke indicate that endovascular therapy is not superior to standard treatment with intravenous t-PA. (Funded by the Italian Medicines Agency, ClinicalTrials.gov number, NCT00640367.).

Published
2013

2. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset

Author

Lorenzano, S, Toni, D, Collaborators : Federico F, TESPI trial I. n. v. e. s. t. i. g. a. t. o. r. s., Rasura, M, Bovi, P, Comi, G, Orlandi, Giovanni, Di Lazzaro, V, Magoni, M, Stanzione, P, Cavazzuti, M, Gandolfo, C, Tola, Mr, Furlan, M, Bruscoli, M, Agnelli, G, Pozzessere, C, Nencini, P, Vinattieri, A, Valente, M, Perini, F, Tassinari, T, Carolei, A, Bettoni, L, Promis, P, and Melis, F.

Subjects
Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, elderly, Brain Ischemia, law.invention, Randomized controlled trial, law, Modified Rankin Scale, Internal medicine, medicine, Humans, media_common.cataloged_instance, intravenous thrombolysis, rt-pa, Thrombolytic Therapy, Prospective Studies, European union, Prospective cohort study, media_common, Aged, 80 and over, ischaemic stroke, business.industry, Standard treatment, Age Factors, Thrombolysis, Stroke, Clinical trial, Treatment Outcome, Italy, Neurology, Tissue Plasminogen Activator, Relative risk, Physical therapy, Female, business, Follow-Up Studies
Abstract

Rationale Intravenous (i.v.) thrombolysis with recombinant tissue-Plasminogen Activator (rt-PA) (alteplase) within three hours from symptom onset is the only approved treatment of pharmacological revascularization in acute ischaemic stroke. However, the current license limits the use of rt-PA to patients aged ≤80 years due to the lack of evidence of safety and efficacy of this treatment in the elderly from randomized clinical trials. This article describes the design of the Thrombolysis in Elderly Stroke Patients in Italy (TESPI) trial planned to fill the lack of controlled data on i.v. thrombolysis in this age category of stroke patients. Aims To collect efficacy and safety data on i.v. alteplase (rt-PA) in patients aged more than 80 years, to demonstrate that the treatment of these patients within three hours of symptoms onset of an acute ischaemic stroke with i.v. rt-PA, compared to patients receiving standard treatment (according to the national guidelines), will result in an improved clinical outcome with a favourable benefit/risk ratio. Design TESPI is a prospective, multicenter, national, open-label, controlled (non-treated group as control), randomized, parallel group trial with blinded evaluation of outcome in patients older than 80 years treated with i.v. rt-PA within three hours after ischaemic stroke onset. The randomization procedure assigns patients to the treatment group with IV alteplase (0.9 mg/kg of body weight) or to standard treatment group with a 1 : 1 basis. A three-month follow-up, when applicable, is performed by a blind assessor. Six hundred patients will be enrolled (300 patients per arm) The study period has been planned to be of three years. Study Outcomes The primary efficacy end-point is the disability at day 90, dichotomized as a favourable outcome (modified Rankin Scale 0–2) or unfavourable outcome (modified Rankin Scale 3–6). The main primary safety end-point is symptomatic intracerebral haemorrhage defined as any hemorrhage at the 22–36 h post-treatment scan combined with neurological deterioration leading to an increase of one or more points at the National Institutes of Health Stroke Scale. The TESPI trial, with the protocol number FARM65KNKY, is registered in the European Union Drug Regulating Authorities Clinical Trials database with the number 2007-006177-88 and in the Stroke Trials Registry of the Washington University Internet Stroke Center.

Published
2012

3. Rate of pregnancy-related relapse in multiple sclerosis

Author

Confavreux C, Hutchinson M, Hours, Mm, Cortinovis Tourniaire, P, Alpérovitch, Moreau T. A., Carton, H., D’Hooghe, M. B., Hommes, O., Biron, A., Grimaud, J., Chauplannaz, G., Latombe, D., Clanet, M., Glau, G. Lau, Rumbach, L., Goas, J. Y., Rouhart, F., Ingue, A. Maz, Roullet, E., Madigand, M., Hautecoeur, P., Brunet, P., Edan, G., Allaire, C., Riffault, G., Leche, J., Benoit, T., Simonin, C., Ziegler, F., Baron, J. C., Rivrain, Y., Dumas, R., Loche, D., Bourrin, J. C., Huttin, B., Delisse, B., Gibert, I., Boulay, C., Verceletto, M., Durand, G., Bonneviot, G., Gil, R., Hedreville, M. A., Cbelair, C. Belair, Poitevin, R. J., Devoize, J. L., Pwyremblewski, P. Wyremblewski, Delestre, F., Setiey, A., Comi, G., Fillippi, M., Ghezzi, A., Martinelli, V., Rossi, P., Zaffaroni, M., Tola, M. R., Amato, M. P., Fioretti, C., Gmeucci, G. Meucci, Inglese, MARIA MATILDE, Mancardi, GIOVANNI LUIGI, Gambi, D., Thomas, A., Cavazzuti, M., Citterio, A., Aheltberg, A. Heltberg, Hansen, H. J., Fernandez, O., Romero, F., Arbizu, T., Hernandez, J. J., Frutos, C. De Andres de, Sclarky, D. Geffner, Benito, Y. Aladro, Yanez, P. Reyes, Aguilar, M., Burguera, J. A., Yaya, R., Dib, W. Bowakim, Sindic, C. J. M., Medaer, R., Roose, H., Geens, K. M. J., Guillaume, D., Zandycke, M. Van, Janssens, J., Cornette, M., Mol, L., Weilbach, F., Flachenecke, P., Hartung, H. P., Haas, J., Tendolkar, I., Sindern, E., Kölmel, H. W., Reichel, D., Rauch, M., Preuss, S., Poser, S., Mauch, E., Strasser Fuchs, S., Kollegger, H., Hawkins, S., Howell, S. J. L., Rees, J. E., Thompson, A., Johnson, M., Boggild, M., Gregory, R. P., Bates, D., Bone, I., Polman, C., Frequin, S., Jongen, P., J. Correia de, Sa, Rio, M. E., Huber, S., Lechner Scott, J., Confavreux, C, Hutchinson, M, Hours, Mm, Cortinovis Tourniaire, P, Moreau, T, the Pregnancy in Multiple Sclerosis, Group, Filippi, Massimo, and Comi, Giancarlo

Subjects
Adult, medicine.medical_specialty, Multiple Sclerosis, Obstetrical, Disease, Relapse rate, Kurtzke Expanded Disability Status Scale, Central nervous system disease, Pregnancy, Recurrence, medicine, Humans, Prospective Studies, Severe disability, Prospective cohort study, Post partum, Analgesia, Epidural, Analgesia, Obstetrical, Breast Feeding, Disease Progression, Female, Postpartum Period, Pregnancy Complications, Medicine (all), business.industry, Obstetrics, Multiple sclerosis, General Medicine, medicine.disease, Surgery, First trimester, Epidural, Gestation, Analgesia, business, Complication, Breast feeding, Postpartum period
Abstract

Background and Methods Multiple sclerosis often occurs in young women, and the effect of pregnancy on the disease is poorly understood. We studied 254 women with multiple sclerosis during 269 pregnancies in 12 European countries. The women were followed during their pregnancies and for up to 12 months after delivery to determine the rate of relapse per trimester and the score on the Kurtzke Expanded Disability Status Scale (range, 0 to 10, with higher scores indicating more severe disability). The relapse rate in each trimester was compared with the rate during the year before the pregnancy. The effects of epidural analgesia and breast-feeding on the frequency of relapse during the first three months post partum and the disability score at 12 months post partum were also determined. Results The mean (±SD) rate of relapse was 0.7±0.9 per woman per year in the year before pregnancy; it was 0.5±1.3 during the first trimester (P=0.03 for the comparison with the rate before pregnancy), 0.6±1.6 during the secon...

Published
1998

4. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature

Author

Gianpaolo Basso, Fabio Facchinetti, Giuseppe Chiossi, Isabella Neri, Milena Cavazzuti, Chiossi, G, Neri, I, Cavazzuti, M, Basso, G, and Facchinetti, F

Subjects
Adult, Pediatrics, medicine.medical_specialty, Ataxia, Prognosi, Diagnosis, Differential, Hyperemesis gravidarum, Pregnancy, Hyperemesis Gravidarum, medicine, Humans, Wernicke Encephalopathy, business.industry, Pregnancy Outcome, Obstetrics and Gynecology, Gestational age, Thiamine Deficiency, General Medicine, medicine.disease, Prognosis, Pregnancy Complication, Pregnancy Complications, Parenteral nutrition, Anesthesia, Vomiting, Female, medicine.symptom, Complication, business, Human
Abstract

Wernicke encephalopathy (WE) is a rare but known complication of severe hyperemesis gravidarum caused by thiamine deficiency. This article presents an unusual case that occurred at our institution and reviews the 48 previously published cases of WE in pregnancy. Considering all the 49 cases, the mean (±standard deviation) patients' age was 26.7 ± 4.9 years, the mean gestational age when WE manifested was 14.3 ± 3.4 weeks, and the mean duration of vomiting and feeding difficulties was 7.7 ± 2.8 weeks. Wernicke's classic triad (confusion, ocular abnormalities, and ataxia) manifested in only 46.9% (23 of 49) of the patients. Confusion affected 63.3% (31 of 49) of the patients, ocular signs 95.9% (47 of 49) and symptoms 57.1% (28 of 49), and ataxia 81.6% (40 of 49). Deterioration of consciousness affected 53.1 % (26 of 49) of the subjects and memory impairment 61.2% (30 of 49). Complete remission of the disease occurred in only 14 of 49 cases. Symptom resolution required months and permanent impairments were common. The overall pregnancy loss rate, directly (spontaneous fetal loss) and indirectly (planned abortion) attributable to WE, was 47.9% (23 of 49). The diagnosis of WE is clinical and can be rapidly confirmed by magnetic resonance imaging. We emphasize the importance of thiamine supplementation to women with prolonged vomiting in pregnancy, especially before intravenous or parenteral nutrition. We also underline the necessity to promptly replace vitamin B1 when neurologic symptoms and/or signs develop in a patient with hyperemesis gravidarum. Copyright © 2006 by Lippincott Williams & Wilkins

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results